The conference will provide an opportunity to present to investors the recent and upcoming news from MedinCell, including :
- Refiling for approval of UzedyTM by its partner Teva, which has confirmed that it plans to commercialize it in the U.S. in the first half of 2023
- Launch by Teva of Phase 3 activities in the U.S. for a second treatment, mdc-TJK
- Launch by MedinCell’s partner, Arthitris Innovation Corporation (AIC), of Phase 3 activities for F14/mdc-CWM, a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
- Advances in the experimental product portfolio at the formulation and pre-clinical stages
Members of the MedinCell management will meet investors during individual meetings.